Corcept Therapeutics Incorporated Stock Working Capital

CORT Stock

USD 57.54 1.62 2.90%

Corcept Therapeutics Incorporated fundamentals help investors to digest information that contributes to Corcept Therapeutics' financial success or failures. It also enables traders to predict the movement of Corcept Stock. The fundamental analysis module provides a way to measure Corcept Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corcept Therapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	354.1 M	313.5 M
Change In Working Capital	8.2 M	8.6 M

Change In Working Capital is likely to gain to about 8.6 M in 2024, whereas Net Working Capital is likely to drop slightly above 313.5 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Corcept Therapeutics Incorporated Company Working Capital Analysis

Corcept Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Corcept Therapeutics Working Capital

354.13 M

Most of Corcept Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corcept Therapeutics Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Corcept Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Corcept Therapeutics is extremely important. It helps to project a fair market value of Corcept Stock properly, considering its historical fundamentals such as Working Capital. Since Corcept Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corcept Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corcept Therapeutics' interrelated accounts and indicators.

	Total Assets	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Short Term Investments	Net Debt	Retained Earnings	Total Current Assets	Current Deferred Revenue	Short Term Debt	Net Tangible Assets	Capital Surpluse	Net Receivables	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.93	0.82	0.5	0.98	1.0	0.93	-0.76	0.9	0.99	0.86	-0.54	1.0	0.86	0.93	-0.6	0.7	0.96	0.46	0.94	0.86
Accounts Payable	0.93		0.89	0.43	0.94	0.91	0.79	-0.51	0.87	0.87	0.89	-0.55	0.93	0.75	0.94	-0.5	0.64	0.83	0.34	0.8	0.87
Total Liab	0.82	0.89		0.43	0.88	0.76	0.64	-0.34	0.8	0.76	0.77	-0.32	0.81	0.71	0.82	-0.38	0.54	0.75	0.34	0.7	0.92
Common Stock	0.5	0.43	0.43		0.44	0.48	0.47	-0.53	0.18	0.51	0.38	0.16	0.44	0.69	0.49	-0.7	0.64	0.46	0.27	0.45	0.27
Property Plant Equipment	0.98	0.94	0.88	0.44		0.97	0.9	-0.67	0.92	0.96	0.86	-0.51	0.98	0.83	0.92	-0.54	0.65	0.95	0.42	0.93	0.91
Total Stockholder Equity	1.0	0.91	0.76	0.48	0.97		0.95	-0.8	0.9	0.99	0.85	-0.57	1.0	0.85	0.92	-0.61	0.7	0.96	0.46	0.94	0.83
Short Term Investments	0.93	0.79	0.64	0.47	0.9	0.95		-0.89	0.79	0.96	0.71	-0.49	0.93	0.79	0.79	-0.59	0.63	0.95	0.28	0.98	0.7
Net Debt	-0.76	-0.51	-0.34	-0.53	-0.67	-0.8	-0.89		-0.58	-0.84	-0.47	0.42	-0.74	-0.72	-0.57	0.56	-0.51	-0.81	-0.36	-0.84	-0.44
Retained Earnings	0.9	0.87	0.8	0.18	0.92	0.9	0.79	-0.58		0.88	0.83	-0.68	0.92	0.77	0.86	-0.38	0.52	0.88	0.53	0.83	0.94
Total Current Assets	0.99	0.87	0.76	0.51	0.96	0.99	0.96	-0.84	0.88		0.81	-0.53	0.98	0.87	0.88	-0.6	0.68	0.98	0.48	0.96	0.82
Current Deferred Revenue	0.86	0.89	0.77	0.38	0.86	0.85	0.71	-0.47	0.83	0.81		-0.39	0.87	0.76	0.94	-0.66	0.78	0.75	0.45	0.71	0.81
Short Term Debt	-0.54	-0.55	-0.32	0.16	-0.51	-0.57	-0.49	0.42	-0.68	-0.53	-0.39		-0.58	-0.33	-0.44	-0.14	0.02	-0.51	-0.34	-0.48	-0.48
Net Tangible Assets	1.0	0.93	0.81	0.44	0.98	1.0	0.93	-0.74	0.92	0.98	0.87	-0.58		0.84	0.93	-0.59	0.69	0.95	0.47	0.93	0.86
Capital Surpluse	0.86	0.75	0.71	0.69	0.83	0.85	0.79	-0.72	0.77	0.87	0.76	-0.33	0.84		0.83	-0.74	0.78	0.87	0.58	0.82	0.73
Net Receivables	0.93	0.94	0.82	0.49	0.92	0.92	0.79	-0.57	0.86	0.88	0.94	-0.44	0.93	0.83		-0.69	0.79	0.82	0.47	0.78	0.85
Long Term Debt Total	-0.6	-0.5	-0.38	-0.7	-0.54	-0.61	-0.59	0.56	-0.38	-0.6	-0.66	-0.14	-0.59	-0.74	-0.69		-0.96	-0.55	-0.3	-0.54	-0.35
Short Long Term Debt	0.7	0.64	0.54	0.64	0.65	0.7	0.63	-0.51	0.52	0.68	0.78	0.02	0.69	0.78	0.79	-0.96		0.63	0.36	0.6	0.51
Net Invested Capital	0.96	0.83	0.75	0.46	0.95	0.96	0.95	-0.81	0.88	0.98	0.75	-0.51	0.95	0.87	0.82	-0.55	0.63		0.45	0.99	0.81
Long Term Investments	0.46	0.34	0.34	0.27	0.42	0.46	0.28	-0.36	0.53	0.48	0.45	-0.34	0.47	0.58	0.47	-0.3	0.36	0.45		0.31	0.5
Net Working Capital	0.94	0.8	0.7	0.45	0.93	0.94	0.98	-0.84	0.83	0.96	0.71	-0.48	0.93	0.82	0.78	-0.54	0.6	0.99	0.31		0.76
Capital Stock	0.86	0.87	0.92	0.27	0.91	0.83	0.7	-0.44	0.94	0.82	0.81	-0.48	0.86	0.73	0.85	-0.35	0.51	0.81	0.5	0.76

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Corcept Therapeutics

Working Capital Over Time

Corcept Capital Surpluse

Capital Surpluse

426.38 Million

At this time, Corcept Therapeutics' Capital Surpluse is comparatively stable compared to the past year.

In accordance with the company's disclosures, Corcept Therapeutics Incorporated has a Working Capital of 354.13 M. This is 16.8% lower than that of the Pharmaceuticals sector and 34.25% lower than that of the Health Care industry. The working capital for all United States stocks is 76.04% higher than that of the company.

Corcept Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corcept Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics of similar companies.

Corcept Therapeutics is currently under evaluation in working capital category among its peers.

Corcept Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corcept Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corcept Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Corcept Fundamentals

	Return On Equity	0.26
	Return On Asset	0.13
	Profit Margin	0.23 %
	Operating Margin	0.26 %
	Current Valuation	5.66 B
	Shares Outstanding	104.78 M
	Shares Owned By Insiders	11.50 %
	Shares Owned By Institutions	85.50 %
	Number Of Shares Shorted	18.8 M
	Price To Earning	30.07 X
	Price To Book	9.44 X
	Price To Sales	9.59 X
	Revenue	482.38 M
	Gross Profit	396.47 M
	EBITDA	108.32 M
	Net Income	106.14 M
	Cash And Equivalents	370.09 M
	Cash Per Share	3.45 X
	Total Debt	151 K
	Debt To Equity	0.01 %
	Current Ratio	8.54 X
	Book Value Per Share	6.10 X
	Cash Flow From Operations	127.04 M
	Short Ratio	17.04 X
	Earnings Per Share	1.26 X
	Price To Earnings To Growth	0.61 X
	Target Price	74.9
	Number Of Employees	352
	Beta	0.46
	Market Capitalization	6.03 B
	Total Asset	621.52 M
	Retained Earnings	402.53 M
	Working Capital	354.13 M
	Current Asset	48.98 M
	Current Liabilities	20.88 M
	Net Asset	621.52 M

About Corcept Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC